Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA

RegulatoryapprovedZIIHERAPositive

AI Analysis

Summary

Roche received FDA approval for two companion diagnostic tests (PATHWAY HER2 and VENTANA HER2 Dual ISH) to identify HER2-positive metastatic gastroesophageal adenocarcinoma patients eligible for treatment with ZIIHERA.

Outcome Details

FDA approval for companion diagnostic tests PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail to identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma patients eligible for ZIIHERA

Importance:7/10

Sentiment:

0.80

FDA approvalcompanion diagnosticHER2-positivegastroesophageal cancerdiagnostic test

Related Companies

$RHHBY

Read the original article

Published by PR Newswire Pharma on August 26, 2026 6:52 PM

Read Original